DK0790308T3 - Cytoksisk lymfocytmodningsfaktor 35kD-underenhed samt monoklonale antistoffer rettet derimod - Google Patents

Cytoksisk lymfocytmodningsfaktor 35kD-underenhed samt monoklonale antistoffer rettet derimod

Info

Publication number
DK0790308T3
DK0790308T3 DK97104682T DK97104682T DK0790308T3 DK 0790308 T3 DK0790308 T3 DK 0790308T3 DK 97104682 T DK97104682 T DK 97104682T DK 97104682 T DK97104682 T DK 97104682T DK 0790308 T3 DK0790308 T3 DK 0790308T3
Authority
DK
Denmark
Prior art keywords
clmf
cells
proteins
relates
present
Prior art date
Application number
DK97104682T
Other languages
English (en)
Inventor
Richard Anthony Chizzonite
Maurice Kent Gately
Ulrich Andreas Gubler
Jeffrey David W Alton J Hulmes
Yu-Ching Eugene Pan
Frank John Podlanski
Alvin Seth Stern
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27412641&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0790308(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of DK0790308T3 publication Critical patent/DK0790308T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Transplantation (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK97104682T 1989-12-22 1990-12-09 Cytoksisk lymfocytmodningsfaktor 35kD-underenhed samt monoklonale antistoffer rettet derimod DK0790308T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45570889A 1989-12-22 1989-12-22
US52093590A 1990-05-09 1990-05-09
US57228490A 1990-08-27 1990-08-27

Publications (1)

Publication Number Publication Date
DK0790308T3 true DK0790308T3 (da) 2007-10-08

Family

ID=27412641

Family Applications (4)

Application Number Title Priority Date Filing Date
DK90123670T DK0433827T3 (da) 1989-12-22 1990-12-09 Cytotoksisk lumfocytmodningsfaktor
DK97104860T DK0790309T3 (da) 1989-12-22 1990-12-09 Cytotoksisk 40kD underenhed af lymfocytmodningsfaktor og monoklonale antistoffer rettet derimod
DK97104656T DK0790255T3 (da) 1989-12-22 1990-12-09 Monoklonale antistoffer som er rettet mod den cytotoksiske lymfocytmodningsfaktor
DK97104682T DK0790308T3 (da) 1989-12-22 1990-12-09 Cytoksisk lymfocytmodningsfaktor 35kD-underenhed samt monoklonale antistoffer rettet derimod

Family Applications Before (3)

Application Number Title Priority Date Filing Date
DK90123670T DK0433827T3 (da) 1989-12-22 1990-12-09 Cytotoksisk lumfocytmodningsfaktor
DK97104860T DK0790309T3 (da) 1989-12-22 1990-12-09 Cytotoksisk 40kD underenhed af lymfocytmodningsfaktor og monoklonale antistoffer rettet derimod
DK97104656T DK0790255T3 (da) 1989-12-22 1990-12-09 Monoklonale antistoffer som er rettet mod den cytotoksiske lymfocytmodningsfaktor

Country Status (11)

Country Link
EP (4) EP0433827B1 (da)
JP (2) JP3238418B2 (da)
AT (4) ATE163675T1 (da)
AU (2) AU6834990A (da)
BG (1) BG60933B2 (da)
CA (3) CA2032653C (da)
DE (4) DE69032086T2 (da)
DK (4) DK0433827T3 (da)
HU (1) HU211879A9 (da)
IE (1) IE904694A1 (da)
NZ (1) NZ236545A (da)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5456924A (en) * 1988-12-23 1995-10-10 Immunotec Research Corporation Ltd. Method of treatment of HIV-seropositive individuals with dietary whey proteins
US5811523A (en) 1988-11-10 1998-09-22 Trinchieri; Giorgio Antibodies to natural killer stimulatory factor
US5457038A (en) * 1988-11-10 1995-10-10 Genetics Institute, Inc. Natural killer stimulatory factor
EP0375045A1 (en) * 1988-12-22 1990-06-27 Duphar International Research B.V New annelated indole derivatives
US6683046B1 (en) 1989-12-22 2004-01-27 Hoffmann-La Roche Inc. Purification and characterization of cytotoxic lymphocyte maturation factor and monoclonal antibodies thereto
US6830751B1 (en) 1994-03-14 2004-12-14 Genetics Institute, Llc Use of IL-12 antagonists in the treatment of rheumatoid arthritis
ZA95960B (en) * 1994-03-14 1995-10-10 Genetics Inst Use of interleukin-12 antagonists in the treatment of autoimmune diseases
ATE381624T1 (de) 1994-05-09 2008-01-15 Oxford Biomedica Ltd Retrovirale vektoren mit verminderter rekombinationsrate
WO1996024369A1 (en) * 1995-02-06 1996-08-15 Genetics Institute, Inc. Formulations for il-12
US5891680A (en) * 1995-02-08 1999-04-06 Whitehead Institute For Biomedical Research Bioactive fusion proteins comprising the p35 and p40 subunits of IL-12
GB9505784D0 (en) * 1995-03-22 1995-05-10 Lynxvale Ltd Anti-tumour treatment
US5853714A (en) * 1995-03-27 1998-12-29 Genetics Institute, Inc. Method for purification of IL-12
US5880146A (en) * 1995-06-07 1999-03-09 Fuji Immunopharmaceuticals Corporation Inhibition of IL-12-induced IFN-γ synthesis by specific bis-phenol compounds as a method of immune modulation
US5853697A (en) * 1995-10-25 1998-12-29 The United States Of America, As Represented By The Department Of Health & Human Services Methods of treating established colitis using antibodies against IL-12
GB9609932D0 (en) * 1996-05-13 1996-07-17 Hoffmann La Roche Use of IL-12 and IFN alpha for the treatment of infectious diseases
AU702379B2 (en) 1996-06-04 1999-02-18 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Novel feline cytokine protein
EP0931156A2 (en) * 1996-10-18 1999-07-28 Valentis Inc. Gene expression and delivery systems and uses
AU726207B2 (en) * 1996-10-18 2000-11-02 Syntex (U.S.A.) Inc. IL-12 gene expression and delivery systems and uses
US6054487A (en) * 1997-03-18 2000-04-25 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids
WO1998041229A1 (en) * 1997-03-19 1998-09-24 F. Hoffmann-La Roche Ag USE OF IL-12p40 AS IMMUNOSTIMULANT
JP2002241398A (ja) * 1997-06-03 2002-08-28 Chemo Sero Therapeut Res Inst 新規なイヌサイトカインタンパク質
US6060284A (en) 1997-07-25 2000-05-09 Schering Corporation DNA encoding interleukin-B30
CA2693296C (en) 1997-12-08 2013-09-10 Merck Patent Gmbh Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
US7026456B1 (en) 1998-01-23 2006-04-11 Hoffman-La Roche, Inc. Antibodies against human IL-12
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
ATE316982T1 (de) 1999-08-09 2006-02-15 Lexigen Pharm Corp Mehrere zytokin-antikörper komplexen
ATE389019T1 (de) * 1999-09-09 2008-03-15 Schering Corp Interleukin-12 p40 und interleukin-b30. kombinationen davon. antikörper. verwendungen in pharmazeutische zusammensetzungen
AU2005202420B2 (en) * 1999-09-09 2008-08-07 Merck Sharp & Dohme Corp. Mammalian cytokines; related reagents and methods
US7090847B1 (en) 1999-09-09 2006-08-15 Schering Corporation Mammalian cytokines; related reagents and methods
EP3184637A1 (en) * 1999-09-09 2017-06-28 Merck Sharp & Dohme Corp. Mammalian interleukin-12 p40 and interleukin b30 complexes, antibodies, uses in pharmaceutical compositions
US7115712B1 (en) 1999-12-02 2006-10-03 Maxygen, Inc. Cytokine polypeptides
JP5179689B2 (ja) 2000-02-11 2013-04-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗体ベース融合タンパク質の循環系内半減期の増強
US6902734B2 (en) 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
BR0207854A (pt) 2001-03-07 2004-08-24 Merck Patent Gmbh Tecnologia de expressão para proteìnas contendo uma porção de anticorpo de isotipo hìbrido
WO2002079415A2 (en) 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
JP4309662B2 (ja) 2001-05-03 2009-08-05 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 腫瘍特異的組換え抗体およびその使用
MXPA04005266A (es) 2001-12-04 2004-10-11 Merck Patent Gmbh Inmunocitocinas con selectividad modulada.
CA2510180C (en) 2002-12-17 2012-09-11 Merck Patent Gesellschaft Mit Beschraenkter Haftung Humanized antibody (h14.18) of the mouse 14.18 antibody binding to gd2 and its fusion with il-2
CA2552590A1 (en) 2004-01-05 2005-07-21 Emd Lexigen Research Center Corp. Interleukin-12 targeted to oncofoetal fibronectin
AU2005319278A1 (en) 2004-12-21 2006-06-29 Centocor, Inc. Anti-IL-12 antibodies, epitopes, compositions, methods and uses
PL1966238T3 (pl) * 2005-12-30 2012-09-28 Merck Patent Gmbh Warianty interleukiny-12p40 o polepszonej stabilności
AU2008328781A1 (en) 2007-11-27 2009-06-04 Ablynx N.V. Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same
US7891807B2 (en) * 2009-06-11 2011-02-22 Ana Nichole Mansuy Decorative eyeglass temples
BR112018069776A2 (pt) 2016-03-29 2019-02-05 Janssen Biotech Inc tratamento de psoríase com intervalo de dosagem aumentado de anticorpos anti-il-12 e/ou anti-il-23
US10189151B2 (en) 2016-11-14 2019-01-29 Snap-On Incorporated Compact head body hammer
TW201922780A (zh) * 2017-09-25 2019-06-16 美商健生生物科技公司 以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法
EP3793521A4 (en) 2018-05-18 2022-02-23 Janssen Biotech, Inc. SAFE AND EFFECTIVE METHOD OF TREATING LUPUS WITH AN ANTI-IL12/IL23 ANTIBODY
DK3883606T5 (da) 2018-09-24 2024-01-02 Janssen Biotech Inc Sikker og effektiv fremgangsmåde til behandling af colitis ulcerosa med anti-il12/il23-antistof
EP3972690A4 (en) 2019-05-23 2023-07-05 Janssen Biotech, Inc. METHOD OF TREATMENT OF INFLAMMATORY BOWEL DISEASE USING COMBINATION THERAPY OF ANTIBODIES TO IL-23 AND TNF-ALPHA

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2441636A1 (en) * 1988-11-10 1990-05-10 The Wistar Institute Of Anatomy And Biology Natural killer stimulatory factor
US5457038A (en) * 1988-11-10 1995-10-10 Genetics Institute, Inc. Natural killer stimulatory factor

Also Published As

Publication number Publication date
EP0433827B1 (en) 1998-03-04
JP2002167400A (ja) 2002-06-11
CA2032653A1 (en) 1991-06-23
EP0433827A3 (en) 1992-07-01
JP3238418B2 (ja) 2001-12-17
HU211879A9 (en) 1995-12-28
CA2032653C (en) 2002-05-28
BG60933B2 (bg) 1996-06-28
CA2346997A1 (en) 1991-06-23
ATE369383T1 (de) 2007-08-15
CA2346997C (en) 2007-02-20
NZ236545A (en) 1993-04-28
IE990006A1 (en) 2000-11-01
EP0790308A1 (en) 1997-08-20
EP0790255A3 (en) 2000-03-01
JPH05294999A (ja) 1993-11-09
DE69032086D1 (de) 1998-04-09
IE990005A1 (en) 2000-11-01
JP3375949B2 (ja) 2003-02-10
DE69034247T2 (de) 2008-04-17
DE69034249T2 (de) 2008-05-29
EP0790255A2 (en) 1997-08-20
EP0790255B1 (en) 2007-08-08
CA2572802A1 (en) 1991-06-23
AU5471294A (en) 1994-06-09
ATE368112T1 (de) 2007-08-15
ATE163675T1 (de) 1998-03-15
DE69034249D1 (de) 2007-09-20
EP0790309A1 (en) 1997-08-20
DK0790309T3 (da) 2007-11-05
IE990007A1 (en) 2000-11-01
EP0790308B1 (en) 2007-07-04
AU6834990A (en) 1991-06-27
EP0433827A2 (en) 1991-06-26
DE69034244D1 (de) 2007-08-16
EP0790309B1 (en) 2007-07-25
DK0790255T3 (da) 2007-11-26
DE69032086T2 (de) 1998-09-17
IE904694A1 (en) 1991-07-17
AU674363B2 (en) 1996-12-19
DK0433827T3 (da) 1998-09-28
DE69034244T2 (de) 2008-04-03
DE69034247D1 (de) 2007-09-06
ATE366311T1 (de) 2007-07-15

Similar Documents

Publication Publication Date Title
DK0790308T3 (da) Cytoksisk lymfocytmodningsfaktor 35kD-underenhed samt monoklonale antistoffer rettet derimod
FI864016A (fi) Med rekombinant-dna-teknik erhaollen kolonistimulerande faktor-1.
DE3789859D1 (de) Formen des Koloniestimulierungsfaktors 1.
ATE167519T1 (de) T-zellen-wachstumsfaktor
ATE103494T1 (de) Verwendung von interleukin 2 zur behandlung von leukaemien.
DK0592566T3 (da) IL-6-muteiner med reduceret cysteinantal
IL129855A (en) Immunotrophic Isolated Protein-Related Breastfeeding Protein (CD14), Its Uses, In vitro Method for Immersion in B Cell Tumor and Differentiation and Vaccine Preparation Kit
ZA873743B (en) Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon
Ottmann et al. Proliferative effects of a recombinant human granulocyte colony-stimulating factor (rg-CSF) on highly enriched hematopoietic progenitor cells
ES8703928A1 (es) Un metodo para preparar la proteina factor de estimulacion de colonias (csf-1)recombinante
BG60657B2 (en) Human recombinant interleukin-2 muteins